Amy S. Gargis

Amy S. Gargis

Auto-generated profile, based on publicly available information

Amy S. Gargis

Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2012 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAmy S Gargis
Amy S Gargis
LKLisa Kalman
Lisa Kalman
MBMeredith W Berry
Meredith W Berry
DBDavid P Bick
David P Bick
DDDavid P Dimmock
David P Dimmock
ILIra M Lubin
Ira M Lubin

8 July 2015 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
AGAmy S Gargis
Amy S Gargis
LKLisa Kalman
Lisa Kalman
DBDavid P Bick
David P Bick
CSCristina da Silva
Cristina da Silva
DDDavid P Dimmock
David P Dimmock
ILIra M Lubin
Ira M Lubin

1 December 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
AGAmy S. Gargis
Amy S. Gargis
LKLisa Kalman
Lisa Kalman
ILIra M. Lubin
Ira M. Lubin
Clinical microbiology and public health laboratories are beginning to utilize next-generation sequencing (NGS) for a range of applications. This technology has the potential to transform the field by providing approaches that will complement, or even replace, many conventional laboratory tests. While the benefits of NGS are significant, the complexities of these assays require an evolving set of standards to ensure testing quality. Regulatory and accreditation requirements, professional guidelines, and best practices that help ensure the quality of NGS-based tests are emerging. This review highlights currently available standards and guidelines for the implementation of NGS in the clinical and public health laboratory setting, and it includes considerations for NGS test validation, quality control procedures, proficiency testing, and reference materials.

18 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGAmy S. Gargis
Amy S. Gargis
BCBlake Cherney
Blake Cherney
ACAndrew B. Conley
Andrew B. Conley
HMHeather P. McLaughlin
Heather P. McLaughlin
DSDavid Sue
David Sue
Widespread release of Bacillus anthracis (anthrax) or Yersinia pestis (plague) would prompt a public health emergency. During an exposure event, high-quality whole genome sequencing (WGS) can identify genetic engineering, including the introduction of antimicrobial resistance (AMR) genes. Here, we developed rapid WGS laboratory and bioinformatics workflows using a long-read nanopore sequencer (MinION) for Y. pestis (6.5 h) and B. anthracis (8.5 h) and sequenced strains with different AMR profiles. Both salt-precipitation and silica-membrane extracted DNA were suitable for MinION WGS using both rapid and field library preparation methods. In replicate experiments, nanopore quality metrics were defined for genome assembly and mutation analysis. AMR markers were correctly detected and >99% coverage of chromosomes and plasmids was achieved using 100,000 raw sequencing reads. While chromosomes and large and small plasmids were accurately assembled, including novel multimeric forms of the Y. pestis virulence plasmid, pPCP1, MinION reads were error-prone, particularly in homopolymer regions. MinION sequencing holds promise as a practical, front-line strategy for on-site pathogen characterization to speed the public health response during a biothreat emergency.

8 October 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAmy S Gargis
Amy S Gargis
MKMaria Karlsson
Maria Karlsson
APAshley L Paulick
Ashley L Paulick
KAKaren F Anderson
Karen F Anderson
MAMichelle Adamczyk
Michelle Adamczyk
LWLisa Winston
Lisa Winston
Antimicrobial susceptibility testing (AST) is not routinely performed for Clostridioides difficile and data evaluating minimum inhibitory concentrations (MICs) are limited. We performed AST and whole genome sequencing (WGS) for 593 C. difficile isolates collected between 2012-2017 through the Centers for Disease Control and Prevention’s Emerging Infections Program. MICs to six antimicrobial agents (ceftriaxone, clindamycin, meropenem, metronidazole, moxifloxacin, and vancomycin) were determined using the reference agar dilution method according to Clinical and Laboratory Standards Institute guidelines. WGS was performed on all isolates to detect the presence of genes or mutations previously associated with resistance. Among all isolates, 98.5% displayed a vancomycin MIC ≤ 2 μg/mL and 97.3% displayed a metronidazole MIC ≤ 2 μg/mL. Ribotype 027 (RT027) isolates displayed higher vancomycin MICs (MIC50: 2 μg/mL; MIC90: 2 μg/mL) than non-RT027 isolates (MIC50: 0.5 μg/mL; MIC90: 1 μg/mL) (P < 0.01). No vanA/B genes were detected. RT027 isolates also showed higher MICs to clindamycin and moxifloxacin and were more likely to harbor associated resistance genes or mutations. Elevated MICs to antibiotics used for treatment of C. difficile infection were rare and there was no increase in MICs over time. The lack of vanA/B genes or mutations consistently associated with elevated vancomycin MICs suggests there are multifactorial mechanisms of resistance. Ongoing surveillance of C. difficile using reference AST and WGS to monitor MIC trends and the presence of antibiotic resistance mechanisms is essential.

1 October 2009 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
SGShaw R. Gargis
Shaw R. Gargis
AGAmy S. Gargis
Amy S. Gargis
HHHarry E. Heath
Harry E. Heath
LHLucie S. Heath
Lucie S. Heath
PLPaul A. LeBlanc
Paul A. LeBlanc
GSGary L. Sloan
Gary L. Sloan
Producer cell immunity to the streptococcolytic enzyme zoocin A, which is a d -alanyl- l -alanine endopeptidase, is due to Zif, the zoocin A immunity factor. Zif has high degrees of similarity to MurM and MurN (members of the FemABX family of proteins), which are responsible for the addition of amino acids to cross bridges during peptidoglycan synthesis in streptococci. In this study, purified peptidoglycans from strains with and without zif were compared to determine how Zif modifies the peptidoglycan layer to cause resistance to zoocin A. The peptidoglycan from each strain was hydrolyzed using the streptococcolytic phage lysin B30, and the resulting muropeptides were separated by reverse-phase high-pressure liquid chromatography, labeled with 4-sulfophenyl isothiocyanate, and analyzed by tandem mass spectrometry in the negative-ion mode. It was determined that Zif alters the peptidoglycan by increasing the proportion of cross bridges containing three l -alanines instead of two. This modification decreased binding of the recombinant target recognition domain of zoocin A to peptidoglycan. Zif-modified peptidoglycan also was less susceptible to hydrolysis by the recombinant catalytic domain of zoocin A. Thus, Zif is a novel FemABX-like immunity factor because it provides resistance to a bacteriolytic endopeptidase by lengthening the peptidoglycan cross bridge rather than by causing an amino acid substitution.